Digital Therapeutics Surge and the Rise of Investment in Scientific Commercialization: Global Early-Stage Funding Report, February 2022
In February 2022, early-stage project financing in the global healthcare sector experienced a minor surge.
According to incomplete statistics, seed/angel round financing events in the global healthcare sector in February40 cases, up from the same period in 202166.67%; Financing AmountRMB 1,512.33 million. Of the 40 financing events, more thanRMB 50 millionof financing total7starting from, among whichJinguan Biology with RMB 200 millionRanks first in financing amount.
In terms of total financing amount,Medical Servicesis the subsector attracting the most capital attention, with most of these financing events occurring overseas and the cumulative funding amounting to approximatelyRMB 403.2 million, accounting for of the total financing amount this month22.67%，Mental HealthNew forces in related services have injected fresh vitality into this field.BiopharmaceuticalsTotal Sector FinancingRMB 330.58 million, accounting for approximately of the total financing amount this month21.85%. Among them,Cell TherapyandAnti-Aging Drug DevelopmentThe company has performed exceptionally well, securing financing respectively.140 million, RMB 63 million。
Data sourced from the Artery Orange Database
Note: This report includes only publicly disclosed financing data, with “several million,” “tens of millions,” “hundreds of millions,” and “nearly 100 million” approximated as RMB 1 million, RMB 10 million, RMB 100 million, and RMB 100 million, respectively. For the purposes of this report, the exchange rates used to convert USD, EUR, and GBP into RMB are 6.3, 7.0, and 8.4, respectively.
In the early-stage investment sector in February, domestic and international financing trends exhibited significant differences.
Data sourced from the VCBeat Database
Note: This report includes only publicly disclosed financing data. Figures described as “several million,” “tens of millions,” “hundreds of millions,” and “nearly 100 million” have been approximated as RMB 1 million, RMB 10 million, RMB 100 million, and RMB 100 million, respectively. In this report, the exchange rates used for converting USD, EUR, and GBP to RMB are 6.3, 7.0, and 8.4, respectively.
Abroad, due to differences in health insurance and the healthcare environment, insurance payment, telemedicine, and physician education enterprises have garnered significant attention.Medical ServicesField byRMB 403.2 million in financingThe total amount is far ahead of the rest.Digital TherapeuticsRanked second in total financing, cumulative amount297.36 millionRMB; most of these companies are primarily focused onMental Health and Health Management。BiopharmaceuticalsA total of four companies in the sector have secured financing, operating respectively inAnti-aging Drugs、Ophthalmic DiseasesTherapeutic drugs,Targeted DrugsandVaccineR&D. Although the total financing amount ranked only third, the financing amounts of biopharmaceutical companies were all at30 million RMBThe above.
In China,Medical DevicesLeading in financing amount, mainly due toJinguan TechnologyA large financing round of RMB 200 million raised the overall level. Jinguang Technology focuses onIntegrated Circuit ChipTechnology andBiotechnologyBy integrating these elements, and with the support of the integrated circuit infrastructure and industrial ecosystem provided by the Shanghai Industrial Technology Research Institute, we will establish an integrated platform for the research, development, and application of customized chips, biotechnology, and cross-disciplinary BTIT products, delivering unique and comprehensive end-to-end BTIT solutions.
Biopharmaceutical Sector8 companiesTotal Corporate Financing170 millionRMB, with the majority of funds flowing intoCell Therapy Companies。
In the digital health sector, which has garnered significant attention abroad, domestic early-stage investment firms did not place any bets this month. China is home to more than 73 digital therapeutics companies, with indications spanning eight major categories and gradually expanding to include major chronic conditions such as cancer and cardiovascular and cerebrovascular diseases, thereby broadening the application scope of digital therapeutics. To gain further insights into China’s digital therapeutics industry during this pivotal growth phase, please refer toVCBeat "China Digital Therapeutics White Paper 2.0"。
Generated in February1,638.33 millionAmong the transaction amounts in Renminbi,67.9%While developments occurred abroad, the majority of domestic capital flowed into Shanghai, a hub for innovation in biopharmaceuticals and medical devices.
Data sourced from the VCBeat database
Note: This report includes only publicly disclosed financing data. Terms such as “several million,” “tens of millions,” “hundreds of millions,” and “nearly 100 million” are approximated as RMB 1 million, RMB 10 million, RMB 100 million, and RMB 100 million, respectively. In this report, the exchange rates used for converting USD, EUR, and GBP to RMB are 6.3, 7.0, and 8.4, respectively.
Among numerous early-stage startups that have secured funding, NearView Bio topped the list with a total financing amount of RMB 200 million. This interdisciplinary technology R&D company was founded by Dr. Chen Chang from the Shanghai Institute of Microsystem and Information Technology, Chinese Academy of Sciences, and incubated by the Shanghai Industrial Technology Research Institute. Focusing on the integration of integrated circuit chip technology and biotechnology, it serves as a cross-sector high-tech enterprise dedicated to the life sciences and general health industries, achieving miniaturization, scale-up production, and chip customization for life science instruments and medical devices.
Ranked second is a foreignContinuing Education in Psychedelic TherapyFluence. The company offers psychedelic therapy courses to clinicians and professionals who engage with patient populations, equipping them to provide mental health counseling and treatment to patients through interactive discussions, demonstrations, self-reflection exercises, and role-playing.
Additionally, Minded, an online psychological counseling and consultation company, completed a seed funding round of approximately RMB 157.5 million in February.
The team comprises a group of entrepreneurs and psychiatry experts, including Stash co-founder David Ronick, Pager co-founder Gaspard de Dreuzy, and Dr. Chris Dennis, a psychiatrist licensed to practice in multiple states who is authorized to issue electronic prescriptions and provide patients with continuous care support. The company advocates for delivering high-quality services at affordable prices, with first-month subscriptions priced at just $10, aiming to ensure affordability even for uninsured patients.
This month, the most closely watched abroad isHeartMental Health. Whether in medical services or digital therapeutics, the ultimate application focus for most funded companies is mental health.
Data sourced from the VCBeat database
Note: This report includes only publicly disclosed financing data. Figures described as “several million,” “tens of millions,” “hundreds of millions,” and “nearly 100 million” are approximated as RMB 1 million, RMB 10 million, RMB 100 million, and RMB 100 million, respectively. In this report, the exchange rates used for converting USD, EUR, and GBP to RMB are 6.3, 7.0, and 8.4, respectively.
The most closely watched niche sectors in early-stage investment in China areCell Therapy, with a total of five companies securing financing. Most of these enterprises did not disclose specific funding amounts; our estimated total financing volume isRMB 140 million. However, the actual amount of financing should be higher than this.
Data sourced from the VBInsight database
Note: This report includes only publicly disclosed financing data. Figures described as “several million,” “tens of millions,” “hundreds of millions,” and “nearly 100 million” are approximated as RMB 1 million, RMB 10 million, RMB 100 million, and RMB 100 million, respectively. For the purposes of this report, the exchange rates used for converting USD, EUR, and GBP to RMB are 6.3, 7.0, and 8.4, respectively.
This month, the investment institution with the most overseas deals wasGaingels, this organization has placed a strong emphasis on digital therapeutics, with its investment portfolio including Minded, Wavely Diagnostics, and the insurance payer company Pay theory.
In China, the most frequent interventions were performed byPeak Fund, its subsidiaries Xianfeng Qiyun and Xianfeng Changqing have cumulatively invested in two companies: Regenerative Bio, an anti-aging drug R&D company in which Xianfeng Changqing participated as an investor, and Yaotang Biology, a gene editing company exclusively invested in by Xianfeng Qiyun.
This month, global early-stage financing remains predominantly technology-driven, with investment keywords largely concentrated in technology-centric sectors such as “artificial intelligence,” “gene technology,” “targeted therapy,” and “new materials.” In contrast, there were fewer financing deals in healthcare service-oriented projects such as “telemedicine,” “physician education,” and “insurance payment.” Moreover, companies receiving investment in these categories are required to obtain corresponding qualifications or skill certifications. Overall, during this month,There are relatively few financing deals driven solely by service models.。
Data sourced from the VCBeat database
Note: This report includes only publicly disclosed financing data, with “several million,” “tens of millions,” “hundreds of millions,” and “nearly 100 million” approximated as RMB 1 million, RMB 10 million, RMB 100 million, and RMB 100 million, respectively. In this report, the exchange rates used for converting USD, EUR, and GBP to CNY are 6.3, 7.0, and 8.4, respectively.
“Whether driven by technology or by service, the most critical factor is to address a specific problem existing in the market.” Commenting on this phenomenon, an early-stage healthcare technology investor stated, “Many hard-core unmet needs currently present in the healthcare sector still require breakthroughs at the technological level.”
Furthermore, an analysis of the enterprises and investment institutions that secured financing this month indicates growing capital enthusiasm for projects focused on the commercialization of scientific research achievements. In addition to NearView Technology, startups with backgrounds in universities and research institutes—such as NourishedRx, ProJenX, Semarion, and Shenji Changhua—are attracting attention. Notably, research entities and academic institutions like the Shanghai Industrial Technology Research Institute and the University of Cambridge are also participating directly. Meanwhile, an increasing number of early-stage technology investment firms are “diving deep” into universities and laboratories to identify suitable projects. Some even engage in the process from 0 to 1, assembling laboratory research teams or findings into early-stage ventures.
Data sourced from the VCBeat Database
Note: This report includes only publicly disclosed financing data. Figures described as “several million,” “tens of millions,” “hundreds of millions,” and “nearly 100 million” are approximated as RMB 1 million, RMB 10 million, RMB 100 million, and RMB 100 million, respectively. For the purposes of this report, the exchange rates used for converting USD, EUR, and GBP to RMB are 6.3, 7.0, and 8.4, respectively.
“This phenomenon has actually been around for a long time. The Boston area is already very mature, with investment firms and industry giants getting involved as early as the project initiation stage,” he continued. As the pace of investment in technological innovation gradually aligns between China and other countries, some domestic companies have emerged in recent years following this model.
“This is also related to technological development in China. In both the innovative drug and medical device industries, a number of companies with innovative capabilities have emerged, and a group of investors has profited from them,” said the investor. “But after that,“Follow Innovation”The dividend has passed, and we need to seekGreater innovation: products and technologies capable of addressing the most fundamental issues and critical “chokepoint” challenges..” Against this backdrop, investors adhering to the philosophy of early-stage technology investment naturally turned their attention to universities and research institutions. Just as there is competition between industries domestically and internationally, researchers in laboratories also compete on the global stage, with the resulting scientific achievements naturally benchmarked against international standards.
"Investors focus on a company's long-term strategic layout, paying close attention to whether its technology is genuinely innovative or merely a modification based on patents already registered by others."Wu Yuxuan, Founder of Yaotang Biologyindicate.
On the one hand, years of basic research have honed scientists’Research Experience and Innovative Thinking, they have a broader vision and do not confine themselves or their teams to merely imitating advanced foreign technologies and products; this isThe Advantages of Scientist Entrepreneurs; on the other hand, scientists sometimes tend to be overlyFocus on Early-Stage Technology R&D, in the subsequentProduct Pipeline Advancement, Clinical Trial Application...and a lack of experience in these areas—issues that are equally critical to corporate development.
“These seemingly mundane operational details can often determine a company’s survival,” said Wu Yuxuan. Unlike academic research in laboratories, technological innovation in the industry must ultimately yield products or solutions applicable in the real world. Therefore, in addition to technological innovation capabilities, investors also pay close attention to a company’s ability to translate early-stage technologies into products, as well as its capabilities in product development and clinical regulatory submissions.
1. Innovative Medical Technology CompanyCND Life SciencesAnnounced the completion of a $5 million second tranche of seed funding. The funds will be used to continue expanding market presence and conducting market education for Syn-One, while also supporting ongoing R&D investment.
2. Digital Health StartupsMarigold HealthAnnouncement of Completion$6 millionseed funding. This round of financing was led byKDT VenturesandFelicis VenturesLead,FLARE Capital Partners, Epsilon Health Investors, Tau Ventures, Springtie Investments, and Stand Together VenturesParticipate in it. The company intends to use the funds to build its peer employee workforce and expand into the new federal states.
3. Mental Health Management PlatformHealthRhythmsAnnounces Receipt ofGSR Ventures and Kleiner Perkins Caufield & ByersFounding MembersBrook ByersLead$11 millionSeed Funding. Health Rhythms offers a more comprehensive, clinically grounded mental health management platform by seamlessly collecting data on daily behaviors and routines. Its core solution leverages deep machine learning and predictive analytics to create novel health assessments and real-time personalized interventions, thereby enhancing the care experience for patients, health plans, payers, and research institutions.
4. AI-Driven Gene Analysis StartupsNostos GenonomyCompleted one round of 5€0 millionseed financing, with investors including42CAP, Frontline Ventures, Amino Collective, and Entrepreneur First. The company’s disease identification platform, AION, can identify genetic variants responsible for more than 10,000 diseases, reducing diagnostic time from an average of 12 hours to under two minutes. Following this round of financing, Nostos Genomics will further expand its team and enter new markets, including the United States.
5. Cincinnati StartupsPay theoryCompleted$2 millionSeed round financing, this round of financing was led by a venture capital firm based in Washington, D.C.Zeal Capital PartnersLead. Pay Theory is a payment platform offered by family-tech SaaS providers to education, healthcare, childcare, and children’s activity service providers. By creating simple, elegant, and impactful financial solutions, Pay Theory ensures that families can stay connected with their most important service providers, while giving SaaS vendors a unique channel to generate new revenue streams. The funding secured will be used for product development and talent acquisition in sales, finance, and software development, as well as to strengthen its relationships with SaaS vendors and service providers.
6. Focused on the R&D of small RNA nucleic acid therapeuticsiMA Biotech(ExoRNA Bio) Announces Completion of Angel Round Financing, with Initial Funding AmountTens of millions of yuan, by a renowned investment institutionCDH Investments’ VGC Fund Led the Round, with a Well-Known Domestic CRO Participating in the Follow-on InvestmentThis round of financing will be primarily allocated to the research, development, and production of nucleic acid therapeutics for neurological disorders, as well as for diseases caused by superbugs and viral infections. In the future, ExoRNA Bio will leverage Professor Zhang Chenyu’s proprietary third-generation in vivo delivery platform for RNAi therapeutics to provide innovative treatment solutions for unmet clinical needs.
7. Healthcare IT ServicesKoda HealthAcquisition3.5 millionUSDseed funding, with this round of financing led byEcliptic CapitalLead, andHeadwater Ventures、Sigma Capital、CRCMParticipation. This funding will be used for company scale expansion; within the next six months, the company urgently plans to double its team size and expand its business operations to all 50 states.
8. Indonesia's Health Tech StartupsSirkaAcquisition$2.6 millionSeed round financing, this round of financing was led byAC Ventures and Wavemaker GroupLed by, other participants in this round of financing includeSequoa、YC、Goodwater Capitaland Indonesian singerMaudy Ayunda。
Sirka aims to help people prevent or manage chronic diseases through exercise and dietary management. Following the financing, Sirka will enhance its operational capabilities by conducting research on a wider range of food products and expanding its team of medical advisors. The company’s leadership stated that it will explore research into therapeutic drugs for chronic conditions such as diabetes in the future.
9. Digital Diagnostics CompaniesWavely DiagnosticsAcquisition$2.2 million's seed round of financing, with investors includingAmbit Health Ventures、WXR Fund、WRF Capital、Cascade Seed Fund、Gaingels Spark Fund、HealthTech Capital、Wealthing VC Club、Vantage Partners Texas、Crosstimbers Capital GroupFollowing this round of financing, the company will continue platform development and prepare for the platform’s launch in spring 2022.
10. Digital Health Management CompanyDawn HealthAcquisition$1.8 millionSeed-round financing, this round of financing was led byKindred VenturesLead,Runway Fund andIndividual Investor Lin, Co-founder of Segment Ilya Volodarsky, Intercom co-founder EoghanMcCabe Invested. Dawn Health aims to empower individuals to regain control over their sleep. The company has developed a cognitive behavioral therapy (CBT) program for insomnia that guides users in identifying thoughts and behaviors contributing to sleep disturbances, replacing them with healthier sleep habits.
11. AI-Driven Protein Design CompaniesLi WensuoAcquireZhenFundInvestmentTens of millions of yuanSeed Round Financing: The funds raised in this round will be primarily used for the establishment of wet and dry laboratories, equipment procurement, and team building.
12. Biotechnology CompaniesLinKinVaxAnnouncement of Completion€4.35 million's seed round of financing, which was led by LinKinVax'sCore Shareholders and Early-Stage Investment InstitutionsLeaders, the funds will be used to accelerate the clinical development of a protein-based vaccine platform, which can expedite vaccine supply by leveraging research conducted by the Vaccine Research Institute (VRI).
13. Digital Health Management CompanyEloAnnounced to Receive$5 millionSeed round financing, this round of financing was led byWill Ventures，Gullspång Re:foodParticipation.
14. Wearable Device DevelopersRespira LabsAnnounced Receipt of2.8 millionSeed round financing, this round of financing is led byZentynel Frontier InvestmentsLead, byVentureWell、ImpactAssetswith the participation of several angel investors from the United States and Latin America, raising $1 million in pre-seed funding and securing $1.8 million in grants from the Small Business Innovation Research (SBIR) program, the National Science Foundation (NSF), the National Institutes of Health (NIH), and other startup awards.
The company intends to use the funds to continue developing and manufacturing its chest-worn device, which uses acoustic resonance to assess lung function and identify changes in lung air volume—a capability that is particularly critical for patients with chronic obstructive pulmonary disease (COPD), COVID-19, and asthma.
15. Provider of Continuous Blood Pressure Monitoring TechnologyXinyong TechnologyAnnouncement of CompletionTens of millions of yuanAngel round financing, byFrees FundExclusive investment; the proceeds from this funding round will be primarily allocated to algorithm iteration, sensor R&D, product manufacturing, and the application for and registration of Class II medical device certification.
16. Healthcare Payment Solution ProvidersAlaffia HealthAnnounces Receipt of$5 millionSeed round financing, this round of financing was led byAnhemisLead, investors include 1984 Ventures、Aperture Venture Capital、Tau Ventures、Twin Ventures、Plug and Play Ventures、ERAetc. The company intends to use these funds to expand its business scale and broaden its market reach.
17. Personalized Health Management CompanyBodymatterAnnounces Receipt of$3 millionSeed round financing, investors includeEarly-stage investors, venture capital firms, family offices, and entrepreneurs. The company intends to use these funds to build its core team, with the goal of developing BodyMatter into a leader in the health and wellness industry, providing users with a variety of online and offline digital products, solutions, and offerings.
18、Nurengjie BiotechAnnouncement of CompletionTens of Millions of RMB's angel round of financing, which was led byJinsha RiverJointRunpu MedicalFundLead investment; the financing will be primarily used for team building, development of the technology platform, and early-stage R&D of novel gene therapy drugs.
19. AI Personal TrainerALTISAnnouncement of Completion$7 millionSeed round financing, this round of financing was led byPentaLabLead. Altis provides users with hyper-personalized fitness plans, offering interactive real-time coaching and plan adjustments based on their training progress. With this funding, the company will continue to expand its business coverage.
20. Biotechnology CompanyProJenX Completed$5.1 millionSeed round financing. This round of financing was led byMedical Excellence CapitalThe investment proceeds will be used to fund the early-stage clinical development of the lead candidate product, prosetin, expand the leadership team, and advance other preclinical programs. ProJenX has developed novel brain-penetrant targeted therapies to address debilitating neurological disorders, with an initial focus on amyotrophic lateral sclerosis (ALS). The company was founded based on a long-standing research collaboration between the ALS project and researchers at Columbia University, aiming to rapidly develop and commercialize its primary therapeutic candidate, prosetin, for patients with ALS.
21. Digital Platforms for Electronic Data Capture in Decentralized Clinical Trials in GermanyClimedoAnnounced to Receive€5 million's seed round of financing. This round of financing was led byChristian Wallwiener of Nauta Capital, WestTech Ventures, and WMC HealthcareAll parties are involved. By collecting and processing real-time data in compliance with data protection regulations, Climedo enables companies not only to secure approvals for pharmaceuticals and medical devices but also to conduct post-market surveillance, documenting the safety and performance of products on the market throughout their entire lifecycle. The company will leverage this new capital to expand in Europe and further develop its software solutions.
22. Digital Health CompaniesNourishedRxAnnouncement of Completion$6 millionSeed round financing, this round of financing is led byS2G VenturesLead Investor,Route 66 Ventures、Connecticut Innovations、Primetime Partnersalong with other individual investors participating in the co-investment. This funding will enable NourishedRx to expand its high-tech, high-touch platform, delivering personalized, culturally relevant food solutions to health plan members across China.
23、Yiqun DolphinRecently acquiredTens of millions of yuanangel round of financing. Founded in 2021, Yiqun Haili focuses on building a full-scenario, data-driven platform that integrates data generation, processing, insights, and business applications for pediatrics. The company has established an integrated management platform for children's health and chronic diseases both inside and outside hospitals, led by hospital-side pediatric applications and supplemented by a series of data applications for internet healthcare and home settings.
24. Innovative Cancer Targeted Drug R&D Company Based on Disease Models + AISigLife Sciences(Shenzhen) Co., Ltd. (Signet Therapeutics) announced the completion of funding fromShenhe CapitalAngel++ RoundTens of millions of yuanFinancing Support. It is reported that this round of financing is the third one completed by the company within a year. The funds from this round will be used to accelerate the advancement of three innovative targeted drug development pipelines under research into clinical trials, promote the expansion and application of existing disease model platforms, strengthen the construction of its own R&D team, and enhance independent innovation capabilities.
25. Digital Health CompaniesTympaHealthAnnouncement of Completion$8 millionSeed funding round to accelerate its expansion in the UK, European, and U.S. markets. This round of financing was led by healthcare entrepreneursMaurice FerreandArjun DesaiLed by the lead investor and joined by a consortium of global investors with extensive experience in developing, launching, and scaling cutting-edge medical technologies, includingJim Breyer, Anil Sethi, Martin Varsavsky, Carlos Gallardo, Fred Moll, Elan Katz, Manny Kadre, and Imran HakiM et al. The company employs award-winning patented technology to conduct comprehensive hearing health assessments at the point of care, thereby enabling earlier disease detection and access to cost-effective care.
26. Male Fertility StartupsExSeed HealthAnnouncement of Completion£2.5 millionSeed-round financing, this round of financing was led byAscensionLead Investor,Trifork、Hambro PerksandR42 GroupCo-investment. This investment will drive the company’s further expansion in Europe, where it has teams in London and Copenhagen.
27. Mental Health and Wellness PlatformMindFiCompleted$2 millionSeed Round Financing; Venture Capital Firms Participating in This Round IncludeGlobal Founders CapitalandM Venture Partners. The company intends to use these funds to accelerate the development of its AI-driven products and localization in key markets.
28. ShenzhenJiyin BioCo., Ltd. completedTens of millions of yuanSeed-round financing, this round of financing is led byHechuang CapitalLead investor,Yifeng CapitalCo-investment. The funds raised in this round will be primarily used for team building, early-stage development of the iCAR-NK pipeline series, optimization and upgrading of core technology platforms, and external collaborations. Jiyin Biopharma focuses on the development of universal cell therapies, committed to providing accessible and insurance-affordable tumor immunotherapy products for general patients.
29. A technology transfer enterprise of Tsinghua University, with a key focus on neurological diseases such as amyotrophic lateral sclerosis (ALS)Shenji ChanghuaAnnounced as CompletedTens of millionsSeed Round, this round isBeijing Life Science Park Innovation Investment FundExclusive Investment. The company’s founding team all hail from Tsinghua University. The team has strategically focused on amyotrophic lateral sclerosis (ALS), stroke, Parkinson’s disease (PD), Alzheimer’s disease (AD), and other neurological disorders, with a particular emphasis on neurodegenerative diseases, aiming to ultimately address these major healthcare challenges for humanity.
30. Developer of Novel Cell Carrier MaterialsSemarion Announced as Completed£2.14 millionSeed round financing, this round of financing was led byParkwalk AdvisorsLead Investor,University of Cambridge Seed Funds、Martlet Capital and angel investors participated in the follow-on investment. This funding will support the commercial development of Semarion’s SemaCyte® cell detection platform. It will also enable further expansion of the team and the establishment of additional research partnerships with biopharmaceutical collaborators.
31. Mental Health Counseling PlatformMindedAnnouncement of Completion$25 millionSeed round financing; investors in this round includeStreamlined Ventures, Link Ventures, The Tiger Fund, Unicorn Ventures, Trousdale Ventures, Gaingels, SALT Fund, TheFund, as well as Care.com, Bolt, Gravity Blanket, RXBAR, and Gilt.comFounder of. The proceeds from the financing will be used to expand its footprint across the United States, introduce therapies targeting attention and mood disorders, and develop innovative psychiatric products.
32. A Regenerative Medicine Company Focused on Tissue and Organ Repair and ReconstructionRuilin BiotechMedical Nanjing Co., Ltd. has been completedTens of millions of RMBAngel round financing. This round of financing was led byJiuyou Capital、WinDi CapitalCo-lead investment,DaoLi CapitalCo-investment. It is reported that Ruisheng Technology’s initial product line will primarily focus on the repair of cartilage defects. In the future, through independent research and development, the company plans to leverage technology that organically integrates multi-source cells with 3D-printed biological scaffold materials. This approach aims to develop cost-effective cartilage regeneration products for applications such as the repair of articular hyaline cartilage, osteochondral tissue, and meniscus in orthopedic sports medicine, as well as external ear reconstruction in plastic surgery.
33. Clinical-Stage Biopharmaceutical CompaniesComplement TherapeuticsAnnouncement of Completion€5 millionSeed round financing, this round of financing is led byBioGeneration Ventures(BGV) andForbionLead investment. BGV provided the initial seed funding in early 2021, and Forbion and BGV have now invested additional seed capital. The company also announced the appointment of two experienced industry executives: Dr. Rafiq Hasan as Chief Executive Officer and Dr. John Ford as an Independent Director.
34. A telehealth company focused on reducing adverse drug reactionsPharmD LiveAnnouncement of Completion$1 millionSeed Funding Round. Cynthia Nwaubani, CEO of PharmD Live, stated, “The company will leverage this seed funding to further expand its business foundation and assist physicians in delivering care to patients with chronic conditions. PharmD Live empowers physicians to provide world-class care to their patients.”
35. Deep Technology CompanyTouchlabCompleted$4.8 millionSeed round financing, this round of financing was led byOctopus VenturesLead Investor, Existing InvestorsCreator Fund and Techstart VenturesCo-investment. The company intends to use these funds to strengthen its commercial and technical teams. It produces an electronic skin system that can be wrapped around rigid or soft robots to sense pressure, position, and orientation in real time. Telerobotics is also gaining popularity in the healthcare sector; when deployed, it facilitates communication between healthcare providers and patients, which is expected to reduce the transmission of healthcare-associated infections (HAIs).
36. The world’s first anti-aging biotechnology R&D company powered by artificial intelligence and cloud-based supercomputingRegenerative BioAnnouncement of CompletionTens of millions of dollarsAngel and Angel+ rounds of financing, with the Angel round led byIMO VenturesLead Investor,K2VC (Xianfeng Changqing), Uphonest Capital (Weicheng Capital), Taihill VentureCo-investment, Angel+ round by5Y Capital (Wuyuan Capital)Lead investor,Yael Capital (Ya Yi Capital)Co-investment. In this round of financing, Regenerative Bio will use the funds to enhance its domestic laboratories, optimize its AI screening platform, and promote the scientific anti-aging brand LAIFE.
37. Biotechnology companies focused on combining LNP (lipid nanoparticle) delivery and gene editing technologiesYaotang BiotechCompletedTens of millionsAngel round of financing, byXianfeng QiyunExclusive Investment. Yaotang Biologics develops in vivo gene editing therapies for genetic and cardiovascular diseases by continuously developing and optimizing CRISPR-Cas, base editing, and other next-generation gene editing tools, as well as through innovative improvements to next-generation mRNA production platforms and lipid nanoparticle (LNP) assembly processes.
38. An educational platform specializing in training and certification for psychedelic-assisted therapy and psychedelic integration therapyFluenceCompleted$3 millionSeed Round Financing; Investors in this round includeJLS Fund, Palo Santo, and Neo Kuma; LearnStart, Evolve Ventures, Iter Investments, Baroda Ventures, Matthew Emerman, Michael CottonandNoah Levy. The company will use these funds to launch new courses, training programs, and certification programs in psychedelic therapy, while strengthening the development of training software and expanding its e-learning platform.
39. WuxiKejin BiotechTechnology Co., Ltd. recently announced the completion ofNearly RMB 100 millionangel round of financing, which was led byPower Square CapitalLead investor,Jinpu Health Fundand WuxiJincheng YingyueAngel FundCo-investment. The company has also received strong support from the Administrative Committee of Xidong New City Business District, Xishan District, Wuxi City, including policy incentives for production base construction and subsidies for high-end talent recruitment. The proceeds from this round of financing will be primarily used to advance the Investigational New Drug (IND) applications for the company’s first rare disease product pipeline—pyruvate kinase deficiency—in both China and Europe.
40、Jinguan TechCompletedRMB 200 millionangel round of financing. This round of financing was led byShanghai United InvestmentLead investor,Honghui Fund, Lianxin Capital, Chende CapitalandShanghai Industrial Technology Research InstituteCo-investment. The funds from this round will be used for the research and development, as well as commercialization, of two core BTIT products.